Psoriasis index of quality of life

The Psoriasis Index of Quality of Life (PSORIQoL) is a patient-reported outcome measure which determines the quality of life of patients with psoriasis.[1] It is based on a needs-based approach to quality of life.[2]

Background

The Psoriasis Index of Quality of Life (PSORIQOL) was published in 2003 by Galen Research.[3] The development of the PSORIQOL was a joint effort between the University of Verona, Erasmus University Rotterdam and the University of Sheffield. The content of the PSORIQOL was derived from 62 qualitative interviews with psoriasis patients. The interview transcripts from the three countries were then analyzed for items for the questionnaire. The rest of the development of the PSORIQoL took play in the United Kingdom. Face and content validity of the selected items were determined by a focus group and further interviews. The PSORIQoL was then completed by two new samples of psoriasis patients by mail, in order to confirm validity and reliability. The end result was a 25 item questionnaire.[3]

International Use

The PSORIQOL has been recognized by the National Institute for Health and Care Excellence (NICE) as a suitable tool for assessing the impact of psoriasis on the patient.[4] It has also been used in clinical studies investigating new treatments.[5][6]

References

  1. ↑ Bronsard V, Paul C, Prey S, Puzenat E, Gourraud PA, Aractingi S, Aubin F, Bagot M, Cribier B, Joly P, Jullien D, Le Maitre M, Richard-Lallemand MA, Ortonne JP (Apr 2010). "What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature.". Journal of the European Academy of Dermatology and Venereology : JEADV. 24 Suppl 2: 17–22. doi:10.1111/j.1468-3083.2009.03563.x. PMID 20443996.
  2. ↑ Bhosle, Monali J.; Kulkarni, Amit; Feldman, Steven R.; Balkrishnan, Rajesh (2006). "Quality of life in patients with psoriasis". Health and Quality of Life Outcomes. 4 (35): 35. doi:10.1186/1477-7525-4-35. PMC 1501000Freely accessible. PMID 16756666.
  3. 1 2 McKenna, SP; Cook, SA; Whalley, D; Doward, LC; Richards, HL; Griffiths, CE; Van Assche, D (Aug 2003). "Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials". The British journal of dermatology. 149 (2): 323–31. doi:10.1046/j.1365-2133.2003.05492.x. PMID 12932239.
  4. ↑ "Psoriasis: management of psoriasis" (PDF). Nice.org.uk. National Institute for Health and Clinical Excellence. Retrieved 2 December 2013.
  5. ↑ "A double blind, randomized, placebo controlled, multicenter, dose finding study of oral AEB071 assessing Psoriasis Area and Severity Index (PASI) respoonse as a function of dose and treatment duration (primary outcome) in patients with plaque psoriasis". EU Clinical Trials Register. European Medicines Agency. Retrieved 2 December 2013.
  6. ↑ Cozzani, E.; Borrini, V; Pennella, A; Burlando, M; Cardo, P; Rebora, A; Parodi, A. (Dec 2010). "The quality of life in Italian psoriatic patients treated with biological drugs". Giornale Italiano Di Dermatologia E Venereologia. 145 (6): 709–712. PMID 21139547.
This article is issued from Wikipedia - version of the 7/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.